- Company optimizing lead compounds to file IND application and initiate first-in-human clinical trials targeting senescent cells in pulmonary disorders - Funding will be used to drive R&D, advance clinical pipeline and expand scientific team SUNNYVALE, Calif., December 3, 2020-- Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $12M Seed financing round. The round was led by Khosla Ventures, with participation from Longevity Fund, Refactor Capital, Shanda and additional investors.